Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) insider Barbara White purchased 2,479 shares of Corbus Pharmaceuticals Holdings stock in a transaction that occurred on Friday, August 11th. The shares were bought at an average price of $6.05 per share, with a total value of $14,997.95. Following the transaction, the insider now owns 171,214 shares of the company’s stock, valued at approximately $1,035,844.70. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Corbus Pharmaceuticals Holdings, Inc. (CRBP) traded up 6.410% during midday trading on Friday, reaching $6.225. 538,853 shares of the company’s stock traded hands. The stock’s market cap is $312.62 million. Corbus Pharmaceuticals Holdings, Inc. has a one year low of $2.95 and a one year high of $10.78. The stock’s 50 day moving average price is $6.27 and its 200-day moving average price is $7.09.

Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) last posted its quarterly earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($0.15) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.19) by $0.04. Corbus Pharmaceuticals Holdings had a negative return on equity of 126.20% and a negative net margin of 1,001.77%. The company had revenue of $0.35 million for the quarter, compared to analysts’ expectations of $0.50 million. Equities analysts predict that Corbus Pharmaceuticals Holdings, Inc. will post ($0.73) earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: “Barbara White Buys 2,479 Shares of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Stock” was first reported by Daily Political and is the sole property of of Daily Political. If you are viewing this piece of content on another publication, it was illegally copied and reposted in violation of US & international copyright and trademark law. The legal version of this piece of content can be viewed at https://www.dailypolitical.com/2017/08/11/barbara-white-buys-2479-shares-of-corbus-pharmaceuticals-holdings-inc-nasdaqcrbp-stock.html.

A number of hedge funds and other institutional investors have recently bought and sold shares of CRBP. Vanguard Group Inc. boosted its position in Corbus Pharmaceuticals Holdings by 24.5% in the second quarter. Vanguard Group Inc. now owns 1,563,408 shares of the biopharmaceutical company’s stock worth $9,850,000 after buying an additional 307,979 shares in the last quarter. Northern Trust Corp boosted its position in Corbus Pharmaceuticals Holdings by 814.3% in the second quarter. Northern Trust Corp now owns 482,337 shares of the biopharmaceutical company’s stock worth $3,039,000 after buying an additional 429,584 shares in the last quarter. Raymond James Financial Services Advisors Inc. boosted its position in Corbus Pharmaceuticals Holdings by 5.5% in the first quarter. Raymond James Financial Services Advisors Inc. now owns 403,886 shares of the biopharmaceutical company’s stock worth $3,332,000 after buying an additional 21,125 shares in the last quarter. Artal Group S.A. acquired a new position in Corbus Pharmaceuticals Holdings during the second quarter worth approximately $1,575,000. Finally, Geode Capital Management LLC boosted its position in Corbus Pharmaceuticals Holdings by 16.5% in the first quarter. Geode Capital Management LLC now owns 201,177 shares of the biopharmaceutical company’s stock worth $1,659,000 after buying an additional 28,492 shares in the last quarter. 28.12% of the stock is currently owned by institutional investors.

CRBP has been the subject of several research reports. Noble Financial reaffirmed a “buy” rating on shares of Corbus Pharmaceuticals Holdings in a report on Saturday, May 6th. Cantor Fitzgerald set a $24.00 price objective on shares of Corbus Pharmaceuticals Holdings and gave the company a “buy” rating in a report on Tuesday, May 9th. Finally, BidaskClub raised shares of Corbus Pharmaceuticals Holdings from a “sell” rating to a “hold” rating in a report on Saturday, July 8th. One investment analyst has rated the stock with a sell rating and four have given a buy rating to the stock. The company has an average rating of “Buy” and a consensus price target of $20.50.

About Corbus Pharmaceuticals Holdings

Corbus Pharmaceuticals Holdings, Inc is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat rare, chronic and serious inflammatory and fibrotic diseases. The Company operates through developing and commercializing therapeutics to treat rare life-threatening inflammatory fibrotic diseases segment.

Insider Buying and Selling by Quarter for Corbus Pharmaceuticals Holdings (NASDAQ:CRBP)

Receive News & Ratings for Corbus Pharmaceuticals Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corbus Pharmaceuticals Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.